Amunix Pharmaceuticals is a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers.
Amunix harnesses clinically validated prodrug technology to advance novel pipeline of T cell engager and cytokine agents that are selectively activated in the tumor microenvironment.
Amunix Pharmaceuticals was founded in 2006 and is headquartered in Mountain View, California.
Amunix Pharmaceuticals' goal is to save cancer patients’ lives through the development and commercialization of breakthrough therapies that harness the immune system.
Amunix has invented XTEN, a validated therapeutic half-life extension technology. The company's current focus is Pro-XTEN, a next-generation protease activated pro-drug platform, which enables selective activation of potent cancer therapies in the tumor microenvironment.
Amunix’s robust technology has been validated through multiple collaborations with leading biopharmaceutical companies including Celgene, Genentech, Janssen, Roche, and Bioverativ (now Sanofi). In addition, XTENylated drugs have been dosed in greater than 200 patients with minimal immunogenicity against XTEN.
Amunix is backed by Omega Funds, Frazier Healthcare Partners, Longitude Capital, Redmile Group, Polaris Partners, Casdin Capital and others. The company raised $73M in a Series A round on Mar 04, 2020.